Search

everythinglearnresearchcommunity

for

Search:↓

Dermmatch is wind and water proof, but requires more hair to look good. Using both Dermmatch and hair fibers together can provide better coverage and a more natural look.

A 32-year-old male started taking 0.5mg of finasteride daily for hair thinning and, after 8 weeks, experienced a 70% reduction in DHT and an increase in estradiol; he is currently in the shedding phase of treatment and questioning if the dosage is correct based on his DHT levels. He began with a lower dose due to already low normal testosterone and DHT levels.

Dutasteride may be better for the brain than Finasteride, potentially increasing dopamine levels and causing fewer side effects. For those switching from Finasteride to Dutasteride to prevent hair loss, it's recommended to continue Finasteride for 3-4 months while starting Dutasteride to avoid shedding due to Dutasteride's long half-life.

The user is considering using dutasteride or finasteride for hair loss and has recurrent folliculitis. Another user suggests treating the folliculitis and notes diffuse thinning.

Hair loss treatments like Minoxidil, finasteride, and RU58841, focusing on their effectiveness and side effects. It also highlights the disparity in medical research funding between hair loss and conditions like endometriosis.

The user experienced positive hair growth and thickness after using a daily blend of 1.2mg Finasteride, 3mg Minoxidil, and other vitamins for five months, with noticeable improvements around the 3.5 to 4-month mark. They reported no side effects and emphasized the importance of patience and consistency with the treatment.

Mixing topical finasteride with essengen f and stemoxydine creates 0.25mg dose in 2ml. Minoxidil max suggests mixing 8.5ml essengen f with 60ml solvent for 0.25mg dose in 1ml.

The user shared impressive hair regrowth progress after 3 months using topical finasteride and minoxidil, noting initial libido reduction that normalized. Other users discussed lighting differences in photos, shared personal experiences, and emphasized the importance of consistency for continued results.

KX-826 failed Phase III trials due to high placebo effects, patient compliance issues, COVID-19 side effects, and detection method deviations. KX-826 is now marketed as a cosmetic and approved for combination with Minoxidil.

The conversation discusses a hair loss treatment formulation containing cyclosporin, minoxidil, and tacrolimus, and mentions ongoing research on hair color reversal. The treatment showed high efficacy in restoring hair color in trials with 40 to 50 people.

The conversation discusses the effectiveness of a hair loss treatment called CB (Breezula) in comparison to Pyrilutamide, and its potential when combined with Finasteride. There is uncertainty about when or if phase 3 trials for Breezula will begin.

The conversation is about alternatives to finasteride for hair loss, with suggestions including fluridil, oral minoxidil, alfatradiol, and cb-03-01. Concerns about finasteride's side effects, including potential breast cancer risk, are also discussed.

A new trial for Verteporfin to treat hair loss will start in LA, led by Dr. Behnam. Users are hopeful it could be a breakthrough treatment.

The conversation is about the approval of Clascoterone (Winlevi) in Canada for hair loss treatment. One user expressed skepticism about its effectiveness due to low concentration.

A 21-year-old experiencing hair loss and depression is planning to start finasteride treatment and is asking for others' experiences. Another user responds positively, stating that finasteride has helped alleviate their depression caused by hair loss.

The conversation discusses skepticism about the effectiveness and formulation of a $10 RU58841 gel from a Korean brand, questioning if ethanol is used to hold the active compounds. Concerns are raised about the feasibility of selling it at such a low price.

Clascoterone is a topical treatment for androgenetic alopecia, showing modest to moderate hair regrowth, and may be available by 2027-2028. It is considered safer than finasteride, with discussions on its effectiveness compared to RU58841 and pyrilutamide.

Finasteride is being discussed as a significant treatment for male baldness, with some users sharing positive experiences and increased confidence, while others express concerns about potential side effects like loss of libido and erectile dysfunction. The conversation highlights differing opinions on the drug's impact and the broader societal implications of changing beauty standards.

The conversation discusses challenges in obtaining finasteride in the Netherlands and explores alternatives like natural DHT blockers and topical finasteride. Suggestions include consulting different doctors or dermatologists and considering cost-effective options like cutting higher-dose tablets.

SCUBE3 is a promising new molecule that can restart hair growth by reawakening dormant hair follicles. Users express skepticism about its availability timeline, with some hoping for release by 2026.

The conversation is about creating a higher concentration of the newly FDA-approved hair loss treatment, Clascoterone (Winlevi), through compounding pharmacies and possibly organizing group purchases. Some users are unfamiliar with Winlevi and are asking for an explanation of the drug.

A breakthrough in hair follicle cultivation using induced pluripotent stem cells (iPSCs) has been achieved, producing large hair follicles suitable for transplantation. Clinical trials for this hair multiplication technology are planned in partnership with Yinguan Biotechnology.

The user underwent a hair transplant in Boston, initially dissatisfied with the results, but later achieved significant improvement in hair density and natural appearance after consulting a different surgeon. They used finasteride, minoxidil, and low-level laser therapy as part of their treatment.

The conversation discusses using red light therapy as a complementary treatment for hair loss alongside finasteride, minoxidil, and other supplements. It suggests investing in reputable, albeit expensive, red light devices for effectiveness and mentions the potential benefits of scalp massage.

Finasteride helped users feel better about hair loss, with some experiencing positive changes in confidence and reduced anxiety. Despite initial concerns, users reported satisfaction with the treatment over several months.

The conversation discusses the potential market release of a hair loss treatment called GT20029 by Anageninc, with users expressing interest and discussing the importance of safety and effectiveness. Some users plan to contact Anageninc to show demand for the product.

Finasteride can reduce semen volume due to prostate shrinkage but doesn't affect fertility. To increase semen volume, consider zinc, lecithin, and reducing finasteride dosage.

The user is using a mixture of crushed finasteride tablets and alfatradiol as a topical treatment for hair loss, applying 1 ml daily, and is asking if this is an effective method or if alfatradiol is a suitable solvent. They mention that others often mix finasteride with minoxidil, but they want to try without it.

PP405 is a new hair loss treatment that may outperform minoxidil and finasteride by growing thick hair in bald areas within four weeks. Its release is expected around 2028, but concerns about its long-term efficacy and cost remain.

Finasteride is generally seen as more successful for hair loss than Dutasteride, with fewer negative experiences reported. Dutasteride is considered more effective but often leads to more complaints, possibly due to higher expectations or improper use.